Y-mAbs to Participate in Upcoming Investor Conferences in October

Rhea-AI Summary

Y-mAbs Therapeutics (Nasdaq: YMAB), a commercial-stage biopharmaceutical company specializing in novel radioimmunotherapy and antibody-based therapeutic products for cancer treatment, has announced its participation in two upcoming investor conferences in October 2024:

1. Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 9:30 a.m. ET
- Location: New York, NY
- Panel: "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes"

2. BMO Oncology Summit:
- Date: Tuesday, October 8, 2024
- Time: 3:00 p.m. ET
- Location: New York, NY
- Fireside chat: "Shifting the Antibody Paradigm"

These conferences provide Y-mAbs with opportunities to showcase its developments in cancer therapeutics and engage with investors.

NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) --  Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that its management team will participate in the following upcoming investor conferences:

Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit
Date: Tuesday, October 8, 2024
Time: 9:30 a.m. ET
Location: New York, NY
Panel: “The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes”

BMO Oncology Summit
Date: Tuesday, October 8, 2024
Time: 3:00 p.m. ET
Location: New York, NY
Fireside chat: “Shifting the Antibody Paradigm”

About Y-mAbs
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform. The Company’s broad and advanced product pipeline includes the anti-GD2 therapy DANYELZA® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy.

Forward-Looking Statements
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, statements about our business model, including financial outlook for 2024 and beyond, including estimated operating expenses, cash burn and DANYELZA product revenue and sufficiency of cash resources and related assumptions; implied and express statements regarding the future of the Company’s business, expectations related to the use of cash and cash equivalents, and the need for, timing and amount of any future financing transaction; expectations with respect to the Company’s future financial performance; and other statements that are not historical facts. Words such as ‘‘anticipate,’’ ‘‘believe,’’ “contemplate,” ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’ ‘‘expect,’’ “hope,” ‘‘intend,’’ ‘‘may,’’ ‘‘might,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘should,’’ ‘‘target,’’ “will,” ‘‘would’,’ “guidance,” “goal,” “objective,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Our product candidates and related technologies are novel approaches to cancer treatment that present significant challenges. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; the risks that actual results of the Company’s restructuring plan and revised business plan will not be as expected; risks associated with the Company’s development work; cost and success of the Company’s product development activities and clinical trials; the risks of delay in the timing of the Company’s regulatory submissions or failure to receive approval of its drug candidates; the risks related to commercializing any approved pharmaceutical product including the rate and degree of market acceptance of product candidates; All statements are subject to the risks described in the "Risk Factors" section included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, and future filings and reports by the Company. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

DANYELZA® and Y-mAbs® are registered trademarks of Y-mAbs Therapeutics, Inc.

Investor Contact:
Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com

FAQ

What investor conferences will Y-mAbs Therapeutics (YMAB) attend in October 2024?

Y-mAbs Therapeutics will participate in two investor conferences on October 8, 2024: the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit and the BMO Oncology Summit, both in New York, NY.

What is the focus of Y-mAbs Therapeutics' (YMAB) presentation at the Oppenheimer conference?

At the Oppenheimer conference, Y-mAbs will participate in a panel discussion titled "The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes" at 9:30 a.m. ET on October 8, 2024.

What type of session will Y-mAbs Therapeutics (YMAB) have at the BMO Oncology Summit?

Y-mAbs will participate in a fireside chat titled "Shifting the Antibody Paradigm" at the BMO Oncology Summit at 3:00 p.m. ET on October 8, 2024.

What is Y-mAbs Therapeutics' (YMAB) main focus as a biopharmaceutical company?

Y-mAbs Therapeutics is focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer.